TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural Set
Cerenovus, Inc. · Decision date Dec 16, 2025
What did the FDA approve?
FDA records P990040/S034 as a supplement to PMA P990040, with the supplement type “Panel Track”. The recorded decision is approval, dated Dec 16, 2025.
FDA approval order statement
The TRUFILL n-BCA Liquid Embolic System is indicated for the embolization of cerebral arteriovenous malformations (AVMs) when pre-surgical devascularization is desired and for embolization of the Middle Meningeal Artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (SDH) as an adjunct to surgery.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Neurology
- Decision date
- Dec 16, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P990040/S034
- Regulatory pathway
- PMA supplement
- Applicant
- Cerenovus, Inc.
- Product code
- SGU
- Decision code
- APPR
- Decision date
- Dec 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Neurovascular Liquid Embolic Agent.
- Applicant
- Cerenovus, Inc.
- Product code
- SGU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P990040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P990040 · Original PMA
TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
P990040/S034 received
Application receipt date recorded by FDA.
P990040/S036 · Related supplement
TRUFILL n-BCA Liquid Embolic System
P990040/S034 · FDA decision
Panel Track
P990040/S038 · Related supplement
TRUFILL n-BCA Liquid Embolic System
P990040/S037 · Related supplement
TRUFILL n-BCA Liquid Embolic System
Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cerenovus, Inc. | PMA approval | Sep 25, 2000 | FDA | |
TRUFILL n-BCA Liquid Embolic SystemP990040/S036 | Cerenovus, Inc. | PMA supplement | Aug 22, 2025 | FDA |
TRUFILL n-BCA Liquid Embolic SystemP990040/S038 | Cerenovus, Inc. | PMA supplement | May 26, 2026 | FDA |
TRUFILL n-BCA Liquid Embolic SystemP990040/S037 | Cerenovus, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code SGU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SQUID Liquid Embolic Agent (LEA)P250009/S001 | Balt USA, LLC | PMA supplement | Oct 16, 2026 | FDA |
SQUID Liquid Embolic Agent (LEA)P250009/S002 | Balt USA, LLC | PMA supplement | Sep 9, 2026 | FDA |
Onyx Liquid Embolic System (LES)P030004/S042 | Ev3 Neurovascular | PMA supplement | Aug 5, 2026 | FDA |
| Balt USA, LLC | PMA approval | Jan 30, 2026 | FDA | |
Onyx Liquid Embolic System (LES)P030004/S035 | Ev3 Neurovascular | PMA supplement | Dec 8, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cerenovus, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6303 Waterford District Dr., Suite 315, Miami, FL, 33126
Sources and methodology
- Original FDA record: P990040/S034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




